Latest news with #Medable
Yahoo
11-06-2025
- Business
- Yahoo
Medable launches programme to enhance eCOA build capabilities in clinical trials
US-based clinical technology provider Medable has launched a programme to supply contract research organisations (CROs) with generative AI-driven, electronic clinical outcome assessment (eCOA) build capabilities in digitally enabled studies. The Partner Program runs on the company's platform and aims to enable CROs to reduce clinical trial timelines by at least 50%, providing both administrative and financial benefits. It is also designed to help CROs generate trial-specific quotes rapidly and enter trial kick-off or bid defence meetings with pre-built digital studies. The Partner Program offers CROs a choice between self-service, managed service, or a hybrid support model, with the aim to deliver higher margin services through the use of generative AI. Among the programme's features are tools for pricing, demo support for bid defence meetings, and a content library to facilitate reuse and scalability. One of its key components is access to Studio, Medable's AI-powered tool for creating, storing and reusing eCOA instruments. Studio is designed to allow CROs to build eCOA assessments and deploy trials independently, providing the flexibility they need to scale their operations. Its features include content libraries, a translational workbench, virtual scheduling capabilities, and an AI-based point-and-click builder. Medable chief customer officer Alison Holland said: 'We have created a better buyer experience for CROs while putting powerful generative AI capabilities into their hands to reduce the time to first-patient-in and ensure greater control over the trial build process. 'Medable's Partner Program also simplifies administration and delivers strategic business advantages. Sponsors will want to work with our partners to move closer to Medable's vision of a one-day study start.' Based in California, Medable offers a digital clinical trials platform that has been used in nearly 400 trials across 70 countries to date. The company recently launched a digital-first long-term follow-up model intended to reduce burdens on sites and participants in cell and gene therapy trials. "Medable launches programme to enhance eCOA build capabilities in clinical trials" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Business Wire
10-06-2025
- Business
- Business Wire
Medable Launches Partner Program for Faster Clinical Trial Startup, Greater Control, and Transparent Pricing
PALO ALTO, Calif.--(BUSINESS WIRE)-- Medable Inc., a leading provider of clinical development technology, today unveiled its new Partner Program, designed to empower contract research organizations (CROs) and other partners with generative AI-driven, self-service eCOA build capabilities for digitally enabled clinical trials. Leveraging the Medable platform, the program eliminates traditional bottlenecks for CROs to accelerate timelines by 50% or more, while delivering administrative and financial benefits, including straightforward, up-front pricing. Medable's Partner Program allows CROs to choose from three models – self-service, managed-service, or a hybrid of both support options. It offers pricing tools, demo support for bid defense meetings, and a portfolio content library to enable reuse and scale. The program provides partial or full enablement to help CROs take control and drive higher margin services, leveraging GenAI to help differentiate themselves in the market. Regardless of support options, the Medable Partner Program offers CROs a better, collaborative eCOA design experience for their sponsors with real-time updates. A major advantage of Medable's Partner Program is access to Studio, Medable's AI-powered solution for building, storing, and reusing eCOA instruments. Designed with CROs in mind, Studio enables self-service eCOA builds and trial deployments, giving CROs more control and flexibility to scale operations. Non-technical staff can easily build assessments in minutes for various studies and therapeutic areas with Medable Studio's rich content libraries, translational workbench, virtual scheduling, AI-based point-and-click builder, and user-friendly interface. In addition to the technical advantages of Medable Studio licensing, Medable's Partner Program simplifies the contractual relationship with upfront, consistent, and competitive pricing, streamlined communications, and on-demand support to reduce the need for change orders. The Medable Partner Program puts CROs in control to confidently: Leverage AI and automation to build higher-quality studies faster and more efficiently; Generate study-specific quotes in seconds using a self-serve pricing calculator; and, Enter any study kick-off or bid defense meeting with a pre-built digital study, ready for instant feedback and updates. 'We have created a better buyer experience for CROs while putting powerful generative AI capabilities into their hands to reduce the time to first-patient-in and ensure greater control over the trial build process,' said Alison Holland, Medable's Chief Customer Officer. 'Medable's Partner Program also simplifies administration and delivers strategic business advantages. Sponsors will want to work with our partners to move closer to Medable's vision of a one-day study start.' Medable has deployed its software-as-a-service platform in more than 300 decentralized and digitally enhanced clinical trials in 70 countries, serving more than one million patients and research participants globally. Customers have achieved impressive results – including 90% eCOA adherence and 50% cost reductions. A Tufts CSDD study also shows that, on average, decentralized trials can achieve net financial benefits from five to 13 times for Phase II and Phase III trials, equating to roughly $10 million ROI and $39 million ROI for an investment on average of $500K in Phase II and $1.5M in Phase III trials, respectively. Recently, the company launched Medable AI and Medable Studio to automatically convert outcomes assessments into fully digital eCOAs in seconds – now accessible on Google Cloud Marketplace. Today, eCOA is foundational to digitally enabled clinical trials. By leveraging Medable's AI-powered, SaaS model and new partnership efficiencies, CROs gain significant cost savings, speed, and scalability. About Medable Medable is on a mission to get effective therapies to people faster. Its digital clinical trials platform enhances speed, scale, and patient access in clinical research, accelerating medicines for thousands of conditions without treatment or cure. Awarded Best Digital Health Solution by the Galien Foundation, Medable's platform has been deployed in nearly 400 trials in 70 countries and 120 languages, serving more than one million patients globally. Medable is a privately held, venture-backed company headquartered in Palo Alto, California, and was listed for the second year in a row on the Inc. 5000 in 2024.
Yahoo
28-05-2025
- Business
- Yahoo
Medable Introduces Long-Term Follow-Up Model for Cell & Gene Therapy (CGT) Trials to Reduce Costs and Improve Patient Access
New digital-first solution enables patient engagement and retention while maintaining scientific rigor throughout 15-year CGT trials PALO ALTO, Calif., May 28, 2025--(BUSINESS WIRE)--Medable Inc., a leading technology platform provider for decentralized clinical trials, today unveiled its digital-first Long-Term Follow-Up (LTFU) model for cell and gene therapy (CGT) trials. Medable's platform reduces the burden on patients and sites involved in complex CGT trials and enhances scientific integrity with sustainable data capture across the FDA-required 15-year follow-up period for certain CGTs, including those using genome-editing techniques like CRISPR-Cas9. This extended monitoring period is essential for tracking delayed adverse events, understanding the durability of the therapy, and ensuring the long-term impact on patients – but can add significant hardships. CGTs offer transformative potential yet they also require prolonged safety monitoring, often spanning 15 years post-treatment. Traditional models for LTFU impose logistical and financial challenges on participants, contributing to lower participation and high attrition rates over time. According to a 2024 survey conducted by the Emily Whitehead Foundation and Catalyst Healthcare Consulting, 20% of CAR T-cell therapy patients stop participating in long-term follow-up altogether, with 80% of that group ceasing participation at or after five years post-treatment. Distance to sites, lack of awareness about local follow-up options, and burdensome travel are frequently cited as key barriers. "Long-term follow-up is essential to ensure the durability and safety of advanced therapies, but the current system isn't working for patients or sponsors," said Dr. Pamela Tenaerts, Chief Medical Officer at Medable. "With our new LTFU model, we're reimagining how post-treatment data is captured - putting patients at the center while ensuring scientific and regulatory rigor." Medable's digital-first LTFU offering includes: Remote and Hybrid Patient Interaction: Patients can engage in follow-up through flexible virtual, in-person, or blended formats that meet their individual needs and life circumstances. Seamless Transition from Parent Trials: Integrated workflows and data continuity ensure a frictionless handoff from interventional studies to long-term observational follow-up. Patient-First Data Capture and Adherence Monitoring: Leveraging mobile technology, patient reported questionnaires and local healthcare providers to track key endpoints and ensure consistent participation over time. Personalized Patient Communication: Ongoing engagement through tailored content, reminders, and support tools to build trust and maintain long-term connection. By embracing a digital, patient-centric approach, Medable's model addresses key gaps in traditional LTFU execution – improving retention, increasing diversity, and reducing the long-term cost burden for both sponsors and sites. Learn more about Medable's new digital-based LTFU model at American Society of Clinical Oncology's (ASCO) 2025 Annual Meeting (May 30-June 3) in Chicago at Medable Booth #10105. About Medable Medable is on a mission to get effective therapies to people faster. Its digital clinical trials platform enhances speed, scale, and patient access in clinical research, accelerating medicines for thousands of conditions without treatment or cure. Awarded Best Digital Health Solution by the Galien Foundation, Medable's platform has been deployed in nearly 400 trials in 70 countries and 120 languages, serving more than one million patients globally. Medable is a privately held, venture-backed company headquartered in Palo Alto, California, and was listed for the second year in a row on the Inc. 5000 in 2024. View source version on Contacts Media Contact: Lisa Barbadora, Barbadora INK for Medable+1 (610) 420-3413lbarbadora@ / media@
Business Wire
28-05-2025
- Health
- Business Wire
Medable Introduces Long-Term Follow-Up Model for Cell & Gene Therapy (CGT) Trials to Reduce Costs and Improve Patient Access
PALO ALTO, Calif.--(BUSINESS WIRE)--Medable Inc., a leading technology platform provider for decentralized clinical trials, today unveiled its digital-first Long-Term Follow-Up (LTFU) model for cell and gene therapy (CGT) trials. Medable's platform reduces the burden on patients and sites involved in complex CGT trials and enhances scientific integrity with sustainable data capture across the FDA-required 15-year follow-up period for certain CGTs, including those using genome-editing techniques like CRISPR-Cas9. This extended monitoring period is essential for tracking delayed adverse events, understanding the durability of the therapy, and ensuring the long-term impact on patients – but can add significant hardships. By embracing a digital, patient-centric approach, Medable's model addresses key gaps in traditional LTFU execution. Share CGTs offer transformative potential yet they also require prolonged safety monitoring, often spanning 15 years post-treatment. Traditional models for LTFU impose logistical and financial challenges on participants, contributing to lower participation and high attrition rates over time. According to a 2024 survey conducted by the Emily Whitehead Foundation and Catalyst Healthcare Consulting, 20% of CAR T-cell therapy patients stop participating in long-term follow-up altogether, with 80% of that group ceasing participation at or after five years post-treatment. Distance to sites, lack of awareness about local follow-up options, and burdensome travel are frequently cited as key barriers. 'Long-term follow-up is essential to ensure the durability and safety of advanced therapies, but the current system isn't working for patients or sponsors,' said Dr. Pamela Tenaerts, Chief Medical Officer at Medable. 'With our new LTFU model, we're reimagining how post-treatment data is captured - putting patients at the center while ensuring scientific and regulatory rigor.' Medable's digital-first LTFU offering includes: Remote and Hybrid Patient Interaction: Patients can engage in follow-up through flexible virtual, in-person, or blended formats that meet their individual needs and life circumstances. Seamless Transition from Parent Trials: Integrated workflows and data continuity ensure a frictionless handoff from interventional studies to long-term observational follow-up. Patient-First Data Capture and Adherence Monitoring: Leveraging mobile technology, patient reported questionnaires and local healthcare providers to track key endpoints and ensure consistent participation over time. Personalized Patient Communication: Ongoing engagement through tailored content, reminders, and support tools to build trust and maintain long-term connection. By embracing a digital, patient-centric approach, Medable's model addresses key gaps in traditional LTFU execution – improving retention, increasing diversity, and reducing the long-term cost burden for both sponsors and sites. Medable Booth # 10105. About Medable Medable is on a mission to get effective therapies to people faster. Its digital clinical trials platform enhances speed, scale, and patient access in clinical research, accelerating medicines for thousands of conditions without treatment or cure. Awarded Best Digital Health Solution by the Galien Foundation, Medable's platform has been deployed in nearly 400 trials in 70 countries and 120 languages, serving more than one million patients globally. Medable is a privately held, venture-backed company headquartered in Palo Alto, California, and was listed for the second year in a row on the Inc. 5000 in 2024.
Yahoo
13-05-2025
- Business
- Yahoo
Medable Releases New Digital Oncology Trial Offering to Reduce Complexity for Sites, Sponsors, Patients, and Caregivers
Integrated solution with self-service capabilities simplifies trial experience for all PALO ALTO, Calif., May 13, 2025--(BUSINESS WIRE)--Medable Inc., a leading provider of clinical development and eCOA technology, today announced its next-generation digital oncology trial offering specifically designed to reduce operational complexity for sites and sponsors while meeting vulnerable cancer patients and their caregivers where they are with accessible, digital tools. Oncology trials have historically been complicated but are becoming increasingly complex due to factors like advanced precision medicine, biomarker incorporation, and the need for broader patient populations, leading to challenges in trial design, recruitment, and data management. At the same time, the FDA is increasingly emphasizing electronic Patient-Reported Outcomes (ePROs) in oncology trials to systematically capture patient perspectives on symptoms, side effects, and quality of life through digital tools, which is changing how sponsors run cancer trials. Medable's newest oncology trial solution combines AI, automation, and differentiated eCOA capabilities to simplify oncology trials with real-time, high-quality patient data capture, remote participation, and continuous oversight. Medable's solution streamlines workflows for sites, which are often managing multiple cancer studies, as well as sponsors and contract research organizations (CROs) that are building nuanced cancer trial protocols. As important, Medable puts patients at the center of the trial, making it easier to collect input directly from patients to turn their lived experiences into tangible data that drives cancer breakthroughs. Medable's digital trial platform is leveraged in global cancer trials across all four phases of research. The foundation of its oncology offering is AI-driven eCOA (including ePRO) technology. From data capture to real-time oversight, it enables the collection of high-quality patient data, including ePROs and digital measures, while supporting greater patient flexibility and delivering real-time oversight for a vulnerable population. Medable eCOA reduces patient burden – especially important in oncology, where protocol complexity is high and patients are often immunocompromised or fatigued – by digitizing assessments, shortening visit times, and enabling remote participation. It also includes protocol-ready libraries, rapid build capabilities, and site-friendly workflows that simplify execution and improve trial responsiveness. "Medable's digital trial platform is the engine that ensures every patient's voice is heard," said Musaddiq Khan, vice president of customer value and oncology lead at Medable. "It is specifically designed to address the biggest challenges in oncology trials, reducing complexity to speed processes with less burden on sites and greater clarity for researchers." Learn more at American Society of Clinical Oncology's (ASCO) 2025 Annual Meeting (May 30-June 3) in Chicago at Medable Booth #10105. About Medable Medable is on a mission to get effective therapies to people faster. Its digital clinical trials platform enhances speed, scale, and patient access in clinical research, accelerating medicines for thousands of conditions without treatment or cure. Awarded Best Digital Health Solution by the Galien Foundation, Medable's platform has been deployed in nearly 400 trials in 70 countries and 120 languages, serving more than one million patients globally. Medable is a privately held, venture-backed company headquartered in Palo Alto, California, and was listed for the second year in a row on the Inc. 5000 in 2024. View source version on Contacts Media Contact: Lisa Barbadora, Barbadora INK for Medable+1 (610) 420-3413lbarbadora@ / media@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
